Limor Zur-Stoller
Plus aucun poste en cours
Profil
Limor Zur-Stoller served as Vice President-Finance & Investor Relations at RadView Software Ltd.
She was also Chief Financial Officer & Treasurer at Gammacan International, Inc. from 2008 to 2011.
From 2008 to 2010, she held the position of Vice President-Finance at Rosetta Genomics Ltd.
Later, she served as Chief Financial Officer & IR Contact at G.F.C Green Fields Capital Ltd.
from 2012 to 2015.
Zur-Stoller completed her undergraduate degree from Tel-Aviv University.
Anciens postes connus de Limor Zur-Stoller
| Sociétés | Poste | Fin |
|---|---|---|
| ROSETTA GENOMICS LTD. | Directeur Financier/CFO | 01/10/2010 |
| G.F.C GREEN FIELDS CAPITAL LTD. | Directeur Financier/CFO | - |
Gammacan International, Inc.
 Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | Directeur Financier/CFO | - |
| RADVIEW SOFTWARE LTD. | Directeur Financier/CFO | - |
Formation de Limor Zur-Stoller
| Tel-Aviv University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| RADVIEW SOFTWARE LTD. | Technology Services |
| ROSETTA GENOMICS LTD. | Health Technology |
| G.F.C GREEN FIELDS CAPITAL LTD. | Finance |
| Entreprise privées | 1 |
|---|---|
Gammacan International, Inc.
Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | Health Technology |
